Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649 · CodeBreaK 301 Phase 3Recruiting
- Lead sponsor
- Amgen (Industry)
- Enrollment
- 450 (estimated)
- Start date
- 17 Jul 2024
- Primary completion
- 25 Sep 2028 (estimated)
- Study completion
- 25 Apr 2032
- Last update posted
- 3 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- FOLFIRI Regimen Drug
- Sotorasib Drug
- Panitumumab Drug
- Bevacizumab-awwb Drug
Conditions and primary outcome
- Metastatic Colorectal Cancer
Primary outcome
PFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) (Up to Approximately 3 Years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedDevelopment of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 Jan 3
PubMed 39752885 (opens in a new tab)DOI 10.6004/jnccn.2024.7067 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06252649 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.